KoningJPalmerPFranksCRMulderDESpeyerJLGreenMDCardioxane-ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev1991;18: 1–19.
2.
SpeyerJLGreenMDZeleniuch-JacquotteAWernzJCReyMSangerJICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol1992;10:117–27.
3.
WexlerLHAndrichMPVenzonDBergSLWeaver-McClureLChenCCRandomized trial of cardioprotective agent, ICRF-187, in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol1996;14:362–72.
4.
VenturiniMMichelottiADel MastroLGalloLCarninoFGarroneOMulticenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol1996;14:3112–20.
5.
SorensenBBastholtLMirzaMRGjeddeSBJakobsenPMouridsenHTThe cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: A Phase I study in metastatic breast cancer. Cancer Chemother Pharmacol1994;34:439–43.
6.
BrubakerLHVogelCLEinhornLHBirchR. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: A Southeastern Cancer Study Group trial. Cancer Treat Rep1986;70: 915–6.
